ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On February 5, 2018, Arch Therapeutics, Inc. (the “Company”) issued a press release announcing the publication of a study in the peer-reviewed journal Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery, detailing the results of the Company’s AC5™ Topical Hemostatic Device clinical trial that was conducted in Western Europe during 2016 (the “Study”). The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The results of the Study were previously reported in summary form in a press release issued by the Company on August 15, 2016, which can be accessed at the following address: https://ir.archtherapeutics.com/press-releases/detail/477/arch-therapeutics-reports-ac5-topical-hemostatic-device.

The disclosure under Item 7.01 (Regulation FD Disclosure) is incorporated herein by reference.

(d) The following exhibits are being filed herewith:

Arch Therapeutics, Inc. Exhibit
EX-99.1 2 tv484833_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical Application   Peer-Reviewed Paper Concludes That AC5TM Provided Safe and Effective Hemostasis Regardless of Whether Patients Were Taking or Not Taking Antiplatelet Therapy.   Framingham MA – February 5,…
To view the full exhibit click here

About ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH)

Arch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s primary product candidates, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The Company’s product candidates rely on its self-assembling peptide technology and are designed to achieve hemostasis in skin wounds, and minimally invasive and open surgical procedures. The Company focuses on developing other product candidates based on its technology platform for use in a range of indications. As of September 30, 2016, the Company had not generated any revenues.